Pieris Pharmaceuticals, Inc. (PIRS) News

Pieris Pharmaceuticals, Inc. (PIRS)

Today's Latest Price: $2.89 USD

0.04 (-1.37%)

Updated Nov 25 4:00pm

Add PIRS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter PIRS News Items

PIRS News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest PIRS News From Around the Web

Below are the latest news stories about Pieris Pharmaceuticals Inc that investors may wish to consider to help them evaluate PIRS as an investment opportunity.

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

The big shareholder groups in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) have power over the company. Insiders often…

Yahoo Finance | September 28, 2020

Recap: Pieris Pharmaceuticals Q2 Earnings

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share …

Benzinga | August 10, 2020

Pieris Pharmaceuticals Announces Oral Presentation of Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at European Society for Medical Oncology (ESMO) Virtual Congress 2020

BOSTON, MA / ACCESSWIRE / July 23, 2020 / Pieris Pharmaceuticals, Inc.

Yahoo | July 23, 2020

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Pieris Pharmaceuticals, Inc. (PIRS) Investigation

NEW YORK, NY / ACCESSWIRE / July 22, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pieris Pharmaceuticals, Inc.

Yahoo | July 22, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pieris Pharmaceuticals, Inc. - PIRS

Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Yahoo | July 21, 2020

The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) * Abbott Laboratories (NYSE: ABT) * ABIOMED, Inc. (NASDAQ: ABMD) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Altimmune Inc (NASDAQ: ALT) * argenx SE - ADR (NASDAQ: ARGX) * AstraZeneca plc (NYSE: AZN) (announced positive Phase 1/2 readout for the coronavirus vaccine it is co-developing with the Oxford University) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) * Beigene Ltd (NASDAQ: BGNE) * BIO-TECHNE Corp (NASDAQ: TECH) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * BioXcel Therapeutics Inc (NASDAQ: BTAI...

Yahoo | July 21, 2020

Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343

Food and Drug Administration (FDA) while Pieris conducts an additional in-use and compatibility study requested by the Agency.

Yahoo | July 20, 2020

Is Pieris Pharmaceuticals, Inc. (PIRS) A Good Stock To Buy?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | June 23, 2020

Edited Transcript of PIRS earnings conference call or presentation 11-May-20 12:00pm GMT

Q1 2020 Pieris Pharmaceuticals Inc Earnings Call

Yahoo | June 8, 2020

Pieris Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

BOSTON, MA / ACCESSWIRE / May 28, 2020 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today that management will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 PM EDT. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Yahoo | May 28, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5917 seconds.